BioSpace News Archive

Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance.

OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on the combination of INB03™ and trastuzumab-deruxtecan (TDxd) for treatment of HER2 positive breast cancer.

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it intends to offer shares of its common stock for sale in an underwritten public offering.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock.

EndoGastric Solutions, Inc.® (EGS) announced that Darin Hammers had been appointed to be President and Chief Executive Officer of the Company and a member of the Board of Directors.

Equillium grants Ono an option to purchase rights to itolizumab.

Gossamer Bio, Inc. today announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).

Entact Bio today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric (ENTAC™) molecules.